國家衛生研究院 NHRI:Item 3990099045/11362
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 967299      線上人數 : 900
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/11362


    題名: Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)
    作者: Lee, K;Bodoky, G;Blanc, J;Siveke, J;Mercade, TM;Wang-Gillam, A;Chen, L;Mirakhur, B;Chen, J;de Jong, F
    貢獻者: National Institute of Cancer Research
    摘要: Introduction: In NAPOLI-1 (NCT01494506), treatment with liposomal irinotecan + 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) significantly increased median overall survival (mOS) vs. 5-FU/LV (6.1 vs. 4.2 months; unstratified hazard ratio [HR]=0.67, 95% confidence interval [CI] 0.49–0.92; P = 0.012) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who had progressed following gemcitabine-based therapy. We investigated the effect of metabolism and nutrition disorders (MNDs) on survival in NAPOLI-1 patients. Methods: This post-hoc analysis explored outcomes in patients with vs. without MNDs (based on MedDRA v14.1), including diabetes mellitus (DM), decreased appetite (DA; which included anorexia, poor appetite, lack of appetite, loss of appetite), hypercholesterolemia (HC), and dyslipidemia. Results: At baseline, 267/417 intent-to-treat (ITT) patients had any MND. Differences in baseline characteristics were observed in some MND subgroups vs. the ITT population: e.g. Karnofsky performance status (DA), gender and race (HC), albumin (DA, HC). Both mOS (3.6 vs. 5.3 months; HR = 1.65, 95% CI 1.25–2.18; P < 0.001) and median progression-free survival (mPFS) (1.6 vs. 2.6 months; HR = 1.42, 95% CI 1.09–1.85; P = 0.010) were significantly lower in patients with (n = 77) vs. those without DA (n = 340). A trend for lower OS was also noted in patients with HC but this did not reach statistical significance. mOS was 4.4 vs. 5.1 months in patients with (n = 47) vs. without HC (n = 370) (HR = 1.37, 95% CI 0.98–1.91; P = 0.063) while mPFS in these populations was 2.3 vs. 2.6 months, respectively (HR = 1.15, 95% CI 0.83–1.60; P = 0.390). No significant difference was observed in survival between patients with (n = 159) vs. without DM (n = 258) or those with (n = 87) vs. without dyslipidemia (n = 330). mOS was 5.6 vs. 4.8 months for patients with vs. without DM (HR = 0.88, 95% CI 0.70–1.11; P = 0.279) while mPFS was 2.8 vs. 2.3 months (HR = 0.86, 95% CI 0.69–1.08; P = 0.191). mOS was 4.7 vs. 5.1 months for patients with vs. without dyslipidemia (HR = 1.13, 95% CI 0.86–1.48; P = 0.375) while mPFS was 2.2 vs. 2.6 months (HR = 1.19, 95% CI 0.91–1.54; P = 0.196). For patients with vs. without any MND, mOS was 4.8 vs. 5.3 months (HR = 1.10, 95% CI 0.87–1.39; P = 0.412) while mPFS was 2.5 vs. 2.6 months (HR = 1.11, 95% CI 0.88–1.39; P = 0.358). In patients treated with nal-IRI+5-FU/LV, mOS (4.6–6.7 vs. 2.7–6.1 months; HR = 0.46–1.05) and mPFS (2.8–4.1 vs. 1.4–1.6 months; HR = 0.24–0.60) were generally improved vs. 5-FU/LV in all subgroups. Safety data, drug-related AEs and dose modifications/discontinuations were broadly similar to the overall NAPOLI-1 study arms. Conclusion: DA at baseline appears to have a prognostic impact on OS (P < 0.001) in mPDAC patients who progressed after gemcitabine-based therapy. The presence of HC may also impact OS. It is important to consider and appropriately manage patients with DA. Treatment with nal-IRI+5-FU/LV provides a benefit regardless of the presence/absence of MNDs. The effect of DM treatment should be explored further.
    日期: 2018-06
    關聯: Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-153.
    Link to: https://doi.org/10.1093/annonc/mdy151.152
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000439970900193
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85081598834
    顯示於類別:[陳立宗] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000439970900193.pdf88KbAdobe PDF247檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋